 | • レポートコード：20QY06-07145 • 出版社/出版日：QYResearch / 2020年6月1日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、142ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社の当調査資料では、多価ワクチンのグローバル市場について種類別（共役ワクチン、不活化およびサブユニットワクチン、弱毒生ワクチン、トキソイドワクチン、組換えワクチン）、用途別（小児、成人）、地域別（北米、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。 ・多価ワクチン市場の概要 ・世界の主要地域別多価ワクチン市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の多価ワクチン市場規模2015-2026：種類別（共役ワクチン、不活化およびサブユニットワクチン、弱毒生ワクチン、トキソイドワクチン、組換えワクチン） ・世界の多価ワクチン市場規模2015-2026：用途別（小児、成人） ・多価ワクチンの北米市場規模2015-2020 ・多価ワクチンのヨーロッパ市場規模2015-2020 ・多価ワクチンの中国市場規模2015-2020 ・多価ワクチンの日本市場規模2015-2020 ・多価ワクチンの東南アジア市場規模2015-2020 ・多価ワクチンのインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 （GlaxoSmithKline, plc (U.K.)、Pfizer, Inc. (U.S.)、Merck & Co., Inc. (U.S.)、Sanofi Pasteur SA (France)、Astellas Pharma Inc. (Japan)、CSL Limited (Australia)、Emergent BioSolutions, Inc. (U.S.)、Johnson & Johnson (U.S.)、MedImmune, LLC (U.S.)、Serum Institute of India Pvt. Ltd. (India)、Bavarian Nordic (Denmark)、Mitsubishi Tanabe Pharma Corporation (Japan)、Daiichi Sankyo (Japan)、Protein Sciences Corporation (U.S.)、Panacea Biotec (India)） ・多価ワクチンの製造コスト分析 ・販売チャネル、流通業者、顧客 ・多価ワクチンの市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Multivalent Vaccines Market
The global Multivalent Vaccines market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026.
Global Multivalent Vaccines Scope and Market Size
The global Multivalent Vaccines market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Multivalent Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Multivalent Vaccines market is segmented into
Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Segment by Application, the Multivalent Vaccines market is segmented into
Pediatrics
Adults
The Multivalent Vaccines market is analysed and market size information is provided by regions (countries). Segment by Application, the Multivalent Vaccines market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Multivalent Vaccines Market Share Analysis
Multivalent Vaccines market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Multivalent Vaccines business, the date to enter into the Multivalent Vaccines market, Multivalent Vaccines product introduction, recent developments, etc.
The major vendors covered:
GlaxoSmithKline, plc (U.K.)
Pfizer, Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc. (U.S.)
Johnson & Johnson (U.S.)
MedImmune, LLC (U.S.)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (U.S.)
Panacea Biotec (India)
Table of Contents
1 Multivalent Vaccines Market Overview
1.1 Multivalent Vaccines Product Scope
1.2 Multivalent Vaccines Segment by Type
1.2.1 Global Multivalent Vaccines Sales by Type (2020-2026)
1.2.2 Conjugate Vaccines
1.2.3 Inactivated and Subunit Vaccines
1.2.4 Live Attenuated Vaccines
1.2.5 Toxoid Vaccines
1.2.6 Recombinant Vaccines
1.3 Multivalent Vaccines Segment by Application
1.3.1 Global Multivalent Vaccines Sales Comparison by Application (2020-2026)
1.3.2 Pediatrics
1.3.3 Adults
1.4 Multivalent Vaccines Market Estimates and Forecasts (2015-2026)
1.4.1 Global Multivalent Vaccines Sales Growth Rate (2015-2026)
1.4.2 Global Multivalent Vaccines Revenue and Growth Rate (2015-2026)
1.4.3 Global Multivalent Vaccines Price Trends (2015-2026)
2 Multivalent Vaccines Estimate and Forecast by Region
2.1 Global Multivalent Vaccines Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Multivalent Vaccines Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Multivalent Vaccines Sales Market Share by Region (2015-2020)
2.2.2 Global Multivalent Vaccines Revenue Market Share by Region (2015-2020)
2.3 Global Multivalent Vaccines Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Multivalent Vaccines Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Multivalent Vaccines Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Multivalent Vaccines Estimates and Projections (2015-2026)
2.4.2 Europe Multivalent Vaccines Estimates and Projections (2015-2026)
2.4.3 China Multivalent Vaccines Estimates and Projections (2015-2026)
2.4.4 Japan Multivalent Vaccines Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Multivalent Vaccines Estimates and Projections (2015-2026)
2.4.6 India Multivalent Vaccines Estimates and Projections (2015-2026)
3 Global Multivalent Vaccines Competition Landscape by Players
3.1 Global Top Multivalent Vaccines Players by Sales (2015-2020)
3.2 Global Top Multivalent Vaccines Players by Revenue (2015-2020)
3.3 Global Multivalent Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multivalent Vaccines as of 2019)
3.4 Global Multivalent Vaccines Average Price by Company (2015-2020)
3.5 Manufacturers Multivalent Vaccines Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Multivalent Vaccines Players (Opinion Leaders)
4 Global Multivalent Vaccines Market Size by Type
4.1 Global Multivalent Vaccines Historic Market Review by Type (2015-2020)
4.1.1 Global Multivalent Vaccines Sales Market Share by Type (2015-2020)
4.1.2 Global Multivalent Vaccines Revenue Market Share by Type (2015-2020)
4.1.3 Global Multivalent Vaccines Price by Type (2014-2020)
4.2 Global Multivalent Vaccines Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Multivalent Vaccines Sales Forecast by Type (2021-2026)
4.2.2 Global Multivalent Vaccines Revenue Forecast by Type (2021-2026)
4.2.3 Global Multivalent Vaccines Price Forecast by Type (2021-2026)
5 Global Multivalent Vaccines Market Size by Application
5.1 Global Multivalent Vaccines Historic Market Review by Application (2015-2020)
5.1.1 Global Multivalent Vaccines Sales Market Share by Application (2015-2020)
5.1.2 Global Multivalent Vaccines Revenue Market Share by Application (2015-2020)
5.1.3 Global Multivalent Vaccines Price by Application (2015-2020)
5.2 Global Multivalent Vaccines Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Multivalent Vaccines Sales Forecast by Application (2021-2026)
5.2.2 Global Multivalent Vaccines Revenue Forecast by Application (2021-2026)
5.2.3 Global Multivalent Vaccines Price Forecast by Application (2021-2026)
3 North America Multivalent Vaccines Market Facts & Figures
3.2 North America Multivalent Vaccines Sales Market Share by Company (2015-2020)
3.3 North America Multivalent Vaccines Sales Market Share by Type (2015-2020)
3.4 North America Multivalent Vaccines Sales Market Share by Application (2015-2020)
4 Europe Multivalent Vaccines Market Facts & Figures
4.2 Europe Multivalent Vaccines Sales Market Share by Company (2015-2020)
4.3 Europe Multivalent Vaccines Sales Market Share by Type (2015-2020)
4.4 Europe Multivalent Vaccines Sales Market Share by Application (2015-2020)
5 China Multivalent Vaccines Market Facts & Figures
5.2 China Multivalent Vaccines Sales Market Share by Company (2015-2020)
5.3 China Multivalent Vaccines Sales Market Share by Type (2015-2020)
5.4 China Multivalent Vaccines Sales Market Share by Application (2015-2020)
6 Japan Multivalent Vaccines Market Facts & Figures
6.2 Japan Multivalent Vaccines Sales Market Share by Company (2015-2020)
6.3 Japan Multivalent Vaccines Sales Market Share by Type (2015-2020)
6.4 Japan Multivalent Vaccines Sales Market Share by Application (2015-2020)
7 Southeast Asia Multivalent Vaccines Market Facts & Figures
7.2 Southeast Asia Multivalent Vaccines Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Multivalent Vaccines Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Multivalent Vaccines Sales Market Share by Application (2015-2020)
8 India Multivalent Vaccines Market Facts & Figures
8.2 India Multivalent Vaccines Sales Market Share by Company (2015-2020)
8.3 India Multivalent Vaccines Sales Market Share by Type (2015-2020)
8.4 India Multivalent Vaccines Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Multivalent Vaccines Business
12.1 GlaxoSmithKline, plc (U.K.)
12.1.1 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Corporation Information
12.1.2 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Business Overview and Total Revenue
12.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.1.4 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Products Offered
12.1.5 GlaxoSmithKline, plc (U.K.) Recent Development
12.2 Pfizer, Inc. (U.S.)
12.2.1 Pfizer, Inc. (U.S.) Multivalent Vaccines Corporation Information
12.2.2 Pfizer, Inc. (U.S.) Multivalent Vaccines Business Overview and Total Revenue
12.2.3 Pfizer, Inc. (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Pfizer, Inc. (U.S.) Multivalent Vaccines Products Offered
12.2.5 Pfizer, Inc. (U.S.) Recent Development
12.3 Merck & Co., Inc. (U.S.)
12.3.1 Merck & Co., Inc. (U.S.) Multivalent Vaccines Corporation Information
12.3.2 Merck & Co., Inc. (U.S.) Multivalent Vaccines Business Overview and Total Revenue
12.3.3 Merck & Co., Inc. (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Merck & Co., Inc. (U.S.) Multivalent Vaccines Products Offered
12.3.5 Merck & Co., Inc. (U.S.) Recent Development
12.4 Sanofi Pasteur SA (France)
12.4.1 Sanofi Pasteur SA (France) Multivalent Vaccines Corporation Information
12.4.2 Sanofi Pasteur SA (France) Multivalent Vaccines Business Overview and Total Revenue
12.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Sanofi Pasteur SA (France) Multivalent Vaccines Products Offered
12.4.5 Sanofi Pasteur SA (France) Recent Development
12.5 Astellas Pharma Inc. (Japan)
12.5.1 Astellas Pharma Inc. (Japan) Multivalent Vaccines Corporation Information
12.5.2 Astellas Pharma Inc. (Japan) Multivalent Vaccines Business Overview and Total Revenue
12.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Astellas Pharma Inc. (Japan) Multivalent Vaccines Products Offered
12.5.5 Astellas Pharma Inc. (Japan) Recent Development
12.6 CSL Limited (Australia)
12.6.1 CSL Limited (Australia) Multivalent Vaccines Corporation Information
12.6.2 CSL Limited (Australia) Multivalent Vaccines Business Overview and Total Revenue
12.6.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.6.4 CSL Limited (Australia) Multivalent Vaccines Products Offered
12.6.5 CSL Limited (Australia) Recent Development
12.7 Emergent BioSolutions, Inc. (U.S.)
12.7.1 Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Corporation Information
12.7.2 Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Business Overview and Total Revenue
12.7.3 Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.7.4 Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Products Offered
12.7.5 Emergent BioSolutions, Inc. (U.S.) Recent Development
12.8 Johnson & Johnson (U.S.)
12.8.1 Johnson & Johnson (U.S.) Multivalent Vaccines Corporation Information
12.8.2 Johnson & Johnson (U.S.) Multivalent Vaccines Business Overview and Total Revenue
12.8.3 Johnson & Johnson (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Johnson & Johnson (U.S.) Multivalent Vaccines Products Offered
12.8.5 Johnson & Johnson (U.S.) Recent Development
12.9 MedImmune, LLC (U.S.)
12.9.1 MedImmune, LLC (U.S.) Multivalent Vaccines Corporation Information
12.9.2 MedImmune, LLC (U.S.) Multivalent Vaccines Business Overview and Total Revenue
12.9.3 MedImmune, LLC (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.9.4 MedImmune, LLC (U.S.) Multivalent Vaccines Products Offered
12.9.5 MedImmune, LLC (U.S.) Recent Development
12.10 Serum Institute of India Pvt. Ltd. (India)
12.10.1 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Corporation Information
12.10.2 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Business Overview and Total Revenue
12.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.10.4 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Products Offered
12.10.5 Serum Institute of India Pvt. Ltd. (India) Recent Development
12.11 Bavarian Nordic (Denmark)
12.11.1 Bavarian Nordic (Denmark) Multivalent Vaccines Corporation Information
12.11.2 Bavarian Nordic (Denmark) Multivalent Vaccines Business Overview and Total Revenue
12.11.3 Bavarian Nordic (Denmark) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Bavarian Nordic (Denmark) Multivalent Vaccines Products Offered
12.11.5 Bavarian Nordic (Denmark) Recent Development
12.12 Mitsubishi Tanabe Pharma Corporation (Japan)
12.12.1 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Corporation Information
12.12.2 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Business Overview and Total Revenue
12.12.3 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.12.4 Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Products Offered
12.12.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Development
12.13 Daiichi Sankyo (Japan)
12.13.1 Daiichi Sankyo (Japan) Multivalent Vaccines Corporation Information
12.13.2 Daiichi Sankyo (Japan) Multivalent Vaccines Business Overview and Total Revenue
12.13.3 Daiichi Sankyo (Japan) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.13.4 Daiichi Sankyo (Japan) Multivalent Vaccines Products Offered
12.13.5 Daiichi Sankyo (Japan) Recent Development
12.14 Protein Sciences Corporation (U.S.)
12.14.1 Protein Sciences Corporation (U.S.) Multivalent Vaccines Corporation Information
12.14.2 Protein Sciences Corporation (U.S.) Multivalent Vaccines Business Overview and Total Revenue
12.14.3 Protein Sciences Corporation (U.S.) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.14.4 Protein Sciences Corporation (U.S.) Multivalent Vaccines Products Offered
12.14.5 Protein Sciences Corporation (U.S.) Recent Development
12.15 Panacea Biotec (India)
12.15.1 Panacea Biotec (India) Multivalent Vaccines Corporation Information
12.15.2 Panacea Biotec (India) Multivalent Vaccines Business Overview and Total Revenue
12.15.3 Panacea Biotec (India) Multivalent Vaccines Sales, Revenue and Gross Margin (2015-2020)
12.15.4 Panacea Biotec (India) Multivalent Vaccines Products Offered
12.15.5 Panacea Biotec (India) Recent Development
13 Multivalent Vaccines Manufacturing Cost Analysis
13.1 Multivalent Vaccines Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Multivalent Vaccines
13.4 Multivalent Vaccines Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Multivalent Vaccines Distributors List
14.3 Multivalent Vaccines Customers
15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Multivalent Vaccines Sales (K Pcs) Growth Rate by Type (2020-2026)
Table 2. Global Multivalent Vaccines Sales (K Pcs) Comparison by Application (2020-2026)
Table 3. Global Market Multivalent Vaccines Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Multivalent Vaccines Sales (K Pcs) by Region (2015-2020)
Table 5. Global Multivalent Vaccines Sales Market Share by Region (2015-2020)
Table 6. Global Multivalent Vaccines Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Multivalent Vaccines Revenue Share by Region (2015-2020)
Table 8. Global Multivalent Vaccines Sales (K Pcs) Forecast by Region (2021-2026)
Table 9. Global Multivalent Vaccines Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Multivalent Vaccines Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Multivalent Vaccines Revenue Share Forecast by Region (2021-2026)
Table 12. Global Multivalent Vaccines (K Pcs) of Key Companies (2015-2020)
Table 13. Global Multivalent Vaccines Sales Share by Company (2015-2020)
Table 14. Global Multivalent Vaccines Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Multivalent Vaccines Revenue Share by Company (2015-2020)
Table 16. Global Multivalent Vaccines by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Multivalent Vaccines as of 2019)
Table 17. Global Multivalent Vaccines Average Price (USD/Pcs) of Key Company (2015-2020)
Table 18. Manufacturers Multivalent Vaccines Manufacturing Sites and Area Served
Table 19. Manufacturers Multivalent Vaccines Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Multivalent Vaccines Players
Table 22. Global Multivalent Vaccines Sales (K Pcs) by Type (2015-2020)
Table 23. Global Multivalent Vaccines Sales Share by Type (2015-2020)
Table 24. Global Multivalent Vaccines Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Multivalent Vaccines Price (K Pcs) by Type (2015-2020)
Table 26. Global Multivalent Vaccines Sales Share by Type (2021-2026)
Table 27. Global Multivalent Vaccines Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Multivalent Vaccines Revenue Share by Type (2021-2026)
Table 29. Global Multivalent Vaccines Price (K Pcs) by Type (2021-2026)
Table 30. Global Multivalent Vaccines Sales (K Pcs) by Application (2015-2020)
Table 31. Global Multivalent Vaccines Sales Share by Application (2015-2020)
Table 32. Global Multivalent Vaccines Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Multivalent Vaccines Price (K Pcs) by Application (2015-2020)
Table 34. Global Multivalent Vaccines Sales (K Pcs) by Application (2021-2026)
Table 35. Global Multivalent Vaccines Sales Share by Application (2021-2026)
Table 36. Global Multivalent Vaccines Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Multivalent Vaccines Revenue Share by Application (2021-2026)
Table 38. Global Multivalent Vaccines Price (K Pcs) by Application (2021-2026)
Table 39. United States Multivalent Vaccines Sales (K Pcs) by Company (2015-2020)
Table 40. United States Multivalent Vaccines Sales Market Share by Company (2015-2020)
Table 41. United States Multivalent Vaccines Sales (K Pcs) by Type (2015-2020)
Table 42. United States Multivalent Vaccines Sales Market Share by Type (2015-2020)
Table 43. United States Multivalent Vaccines Sales (K Pcs) by Application (2015-2020)
Table 44. United States Multivalent Vaccines Sales Market Share by Application (2015-2020)
Table 45. Europe Multivalent Vaccines Sales (K Pcs) by Company (2015-2020)
Table 46. Europe Multivalent Vaccines Sales Market Share by Company (2015-2020)
Table 47. Europe Multivalent Vaccines Sales (K Pcs) by Type (2015-2020)
Table 48. Europe Multivalent Vaccines Sales Market Share by Type (2015-2020)
Table 49. Europe Multivalent Vaccines Sales (K Pcs) by Application (2015-2020)
Table 50. Europe Multivalent Vaccines Sales Market Share by Type (2015-2020)
Table 51. China Multivalent Vaccines Sales (K Pcs) by Company (2015-2020)
Table 52. China Multivalent Vaccines Sales Market Share by Company (2015-2020)
Table 53. China Multivalent Vaccines Sales (K Pcs) by Type (2015-2020)
Table 54. China Multivalent Vaccines Sales Market Share by Type (2015-2020)
Table 55. China Multivalent Vaccines Sales (K Pcs) by Application (2015-2020)
Table 56. China Multivalent Vaccines Sales Market Share by Application (2015-2020)
Table 57. Japan Multivalent Vaccines Sales (K Pcs) by Company (2015-2020)
Table 58. Japan Multivalent Vaccines Sales Market Share by Company (2015-2020)
Table 59. Japan Multivalent Vaccines Sales (K Pcs) by Type (2015-2020)
Table 60. Japan Multivalent Vaccines Sales Market Share by Type (2015-2020)
Table 61. Japan Multivalent Vaccines Sales (K Pcs) by Application (2015-2020)
Table 62. Japan Multivalent Vaccines Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Multivalent Vaccines Sales (K Pcs) by Company (2015-2020)
Table 64. Southeast Asia Multivalent Vaccines Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Multivalent Vaccines Sales (K Pcs) by Type (2015-2020)
Table 66. Southeast Asia Multivalent Vaccines Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Multivalent Vaccines Sales (K Pcs) by Type (2015-2020)
Table 68. Southeast Asia Multivalent Vaccines Sales Market Share by Application (2015-2020)
Table 69. India Multivalent Vaccines Sales (K Pcs) by Company (2015-2020)
Table 70. India Multivalent Vaccines Sales Market Share by Company (2015-2020)
Table 71. India Multivalent Vaccines Sales (K Pcs) by Type (2015-2020)
Table 72. India Multivalent Vaccines Sales Market Share by Type (2015-2020)
Table 73. India Multivalent Vaccines Sales (K Pcs) by Application (2015-2020)
Table 74. India Multivalent Vaccines Sales Market Share by Application (2015-2020)
Table 75. GlaxoSmithKline, plc (U.K.) Corporation Information
Table 76. GlaxoSmithKline, plc (U.K.) Description and Business Overview
Table 77. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product
Table 79. GlaxoSmithKline, plc (U.K.) Recent Development
Table 80. Pfizer, Inc. (U.S.) Corporation Information
Table 81. Pfizer, Inc. (U.S.) Description and Business Overview
Table 82. Pfizer, Inc. (U.S.) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Pfizer, Inc. (U.S.) Multivalent Vaccines Product
Table 84. Pfizer, Inc. (U.S.) Recent Development
Table 85. Merck & Co., Inc. (U.S.) Corporation Information
Table 86. Merck & Co., Inc. (U.S.) Description and Business Overview
Table 87. Merck & Co., Inc. (U.S.) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. Merck & Co., Inc. (U.S.) Multivalent Vaccines Product
Table 89. Merck & Co., Inc. (U.S.) Recent Development
Table 90. Sanofi Pasteur SA (France) Corporation Information
Table 91. Sanofi Pasteur SA (France) Description and Business Overview
Table 92. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. Sanofi Pasteur SA (France) Multivalent Vaccines Product
Table 94. Sanofi Pasteur SA (France) Recent Development
Table 95. Astellas Pharma Inc. (Japan) Corporation Information
Table 96. Astellas Pharma Inc. (Japan) Description and Business Overview
Table 97. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product
Table 99. Astellas Pharma Inc. (Japan) Recent Development
Table 100. CSL Limited (Australia) Corporation Information
Table 101. CSL Limited (Australia) Description and Business Overview
Table 102. CSL Limited (Australia) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. CSL Limited (Australia) Multivalent Vaccines Product
Table 104. CSL Limited (Australia) Recent Development
Table 105. Emergent BioSolutions, Inc. (U.S.) Corporation Information
Table 106. Emergent BioSolutions, Inc. (U.S.) Description and Business Overview
Table 107. Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Product
Table 109. Emergent BioSolutions, Inc. (U.S.) Recent Development
Table 110. Johnson & Johnson (U.S.) Corporation Information
Table 111. Johnson & Johnson (U.S.) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 112. Johnson & Johnson (U.S.) Description and Business Overview
Table 113. Johnson & Johnson (U.S.) Multivalent Vaccines Product
Table 114. Johnson & Johnson (U.S.) Recent Development
Table 115. MedImmune, LLC (U.S.) Corporation Information
Table 116. MedImmune, LLC (U.S.) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 117. MedImmune, LLC (U.S.) Description and Business Overview
Table 118. MedImmune, LLC (U.S.) Multivalent Vaccines Product
Table 119. MedImmune, LLC (U.S.) Recent Development
Table 120. Serum Institute of India Pvt. Ltd. (India) Corporation Information
Table 121. Serum Institute of India Pvt. Ltd. (India) Description and Business Overview
Table 122. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product
Table 124. Serum Institute of India Pvt. Ltd. (India) Recent Development
Table 125. Bavarian Nordic (Denmark) Corporation Information
Table 126. Bavarian Nordic (Denmark) Description and Business Overview
Table 127. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Bavarian Nordic (Denmark) Multivalent Vaccines Product
Table 129. Bavarian Nordic (Denmark) Recent Development
Table 130. Mitsubishi Tanabe Pharma Corporation (Japan) Corporation Information
Table 131. Mitsubishi Tanabe Pharma Corporation (Japan) Description and Business Overview
Table 132. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product
Table 134. Mitsubishi Tanabe Pharma Corporation (Japan) Recent Development
Table 135. Daiichi Sankyo (Japan) Corporation Information
Table 136. Daiichi Sankyo (Japan) Description and Business Overview
Table 137. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Daiichi Sankyo (Japan) Multivalent Vaccines Product
Table 139. Daiichi Sankyo (Japan) Recent Development
Table 140. Protein Sciences Corporation (U.S.) Corporation Information
Table 141. Protein Sciences Corporation (U.S.) Description and Business Overview
Table 142. Protein Sciences Corporation (U.S.) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Protein Sciences Corporation (U.S.) Multivalent Vaccines Product
Table 144. Protein Sciences Corporation (U.S.) Recent Development
Table 145. Panacea Biotec (India) Corporation Information
Table 146. Panacea Biotec (India) Description and Business Overview
Table 147. Panacea Biotec (India) Multivalent Vaccines Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 148. Panacea Biotec (India) Multivalent Vaccines Product
Table 149. Panacea Biotec (India) Recent Development
Table 150. Production Base and Market Concentration Rate of Raw Material
Table 151. Key Suppliers of Raw Materials
Table 152. Multivalent Vaccines Distributors List
Table 153. Multivalent Vaccines Customers List
Table 154. Market Key Trends
Table 155. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 156. Key Challenges
Table 157. Research Programs/Design for This Report
Table 158. Key Data Information from Secondary Sources
Table 159. Key Data Information from Primary Sources
List of Figures
Figure 1. Multivalent Vaccines Product Picture
Figure 2. Global Multivalent Vaccines Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Multivalent Vaccines Market Share by Application in 2020 & 2026
Figure 6. Pediatrics Examples
Figure 7. Adults Examples
Figure 8. Global Multivalent Vaccines Sales (K Pcs) Growth Rate (2015-2026)
Figure 9. Global Multivalent Vaccines Revenue (US$ Million) Growth Rate (2015-2026)
Figure 10. Global Multivalent Vaccines Price Trends Growth Rate (2015-2026) (USD/Pcs)
Figure 11. Global Multivalent Vaccines Revenue Market Share by Region: 2015 VS 2020
Figure 12. Global Multivalent Vaccines Revenue Market Share by Region: 2021 VS 2026
Figure 13. United States Multivalent Vaccines Revenue (Million USD) Growth Rate (2015-2026)
Figure 14. United States Multivalent Vaccines Sales (K Pcs) Growth Rate (2015-2026)
Figure 15. Europe Multivalent Vaccines Revenue (Million USD) Growth Rate (2015-2026)
Figure 16. Europe Multivalent Vaccines Sales (Million USD) Growth Rate (2015-2026)
Figure 17. China Multivalent Vaccines Revenue (Million USD) Growth Rate (2015-2026)
Figure 18. China Multivalent Vaccines Sales (Million USD) and Growth Rate (2015-2026)
Figure 19. Japan Multivalent Vaccines Revenue (Million USD) Growth Rate (2015-2026)
Figure 20. Japan Multivalent Vaccines Sales (Million USD) Growth Rate (2015-2026)
Figure 21. Southeast Asia Multivalent Vaccines Revenue (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Multivalent Vaccines Sales (Million USD) Growth Rate (2015-2026)
Figure 23. India Multivalent Vaccines Revenue (Million USD) Growth Rate (2015-2026)
Figure 24. India Multivalent Vaccines Sales (Million USD) Growth Rate (2015-2026)
Figure 25. Global 5 Largest Multivalent Vaccines Players Market Share by Revenue in Multivalent Vaccines 2015 & 2019
Figure 26. Multivalent Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 27. Global Multivalent Vaccines Revenue Share by Type (2015-2020)
Figure 28. Global Multivalent Vaccines Revenue Growth Rate by Type in 2015 & 2019
Figure 29. Global Multivalent Vaccines Revenue Share by Application (2015-2020)
Figure 30. Global Multivalent Vaccines Revenue Growth Rate by Application in 2015 & 2019
Figure 31. United States Multivalent Vaccines Sales Market Share by Type in 2019
Figure 32. United States Multivalent Vaccines Sales Market Share by Type in 2019
Figure 33. Europe Multivalent Vaccines Sales Market Share by Company in 2019
Figure 34. Europe Multivalent Vaccines Sales Market Share by Type in 2019
Figure 35. Europe Multivalent Vaccines Sales Market Share by Application in 2019
Figure 36. China Multivalent Vaccines Sales Market Share by Company in 2019
Figure 37. China Multivalent Vaccines Sales Market Share by Type in 2019
Figure 38. China Multivalent Vaccines Sales Market Share by Application in 2019
Figure 39. Japan Multivalent Vaccines Sales Market Share by Company in 2019
Figure 40. Japan Multivalent Vaccines Sales Market Share by Type in 2019
Figure 41. Japan Multivalent Vaccines Sales Market Share by Application in 2019
Figure 42. Southeast Asia Multivalent Vaccines Sales Market Share by Company in 2019
Figure 43. Southeast Asia Multivalent Vaccines Sales Market Share by Type in 2019
Figure 44. Southeast Asia Multivalent Vaccines Sales Market Share by Application in 2019
Figure 45. India Multivalent Vaccines Sales Market Share by Company in 2019
Figure 46. India Multivalent Vaccines Sales Market Share by Type in 2019
Figure 47. India Multivalent Vaccines Sales Market Share by Application in 2019
Figure 48. GlaxoSmithKline, plc (U.K.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Pfizer, Inc. (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Merck & Co., Inc. (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. Sanofi Pasteur SA (France) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Astellas Pharma Inc. (Japan) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. CSL Limited (Australia) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Emergent BioSolutions, Inc. (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Johnson & Johnson (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. MedImmune, LLC (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Serum Institute of India Pvt. Ltd. (India) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Bavarian Nordic (Denmark) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Mitsubishi Tanabe Pharma Corporation (Japan) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Daiichi Sankyo (Japan) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Protein Sciences Corporation (U.S.) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Panacea Biotec (India) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Key Raw Materials Price Trend
Figure 64. Manufacturing Cost Structure of Multivalent Vaccines
Figure 65. Manufacturing Process Analysis of Multivalent Vaccines
Figure 66. Multivalent Vaccines Industrial Chain Analysis
Figure 67. Channels of Distribution
Figure 68. Distributors Profiles
Figure 69. Porter's Five Forces Analysis
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
共役ワクチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Conjugate Vaccines market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 5.2% in the forecast period of 2020 to 2025 and will expected to reach USD 14570 million by 2025, from USD 11890 million in 2019. The Conjugate Vaccines …- H7N9ワクチンの世界市場レポート2020 Market Analysis and Insights: Global H7N9 Vaccines Market The global H7N9 Vaccines market was valued at US$ xx million in 2019 and will reach US$ xx million by the end of 2026, growing at a CAGR of xx% during 2020-2026. Global H7N9 Vaccines Scope and Market Size The global H7N9 Vaccines market is se…
- HPV治療ワクチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global HPV Therapeutic Vaccines market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The HPV Therapeutic Vacc…
- 組換えワクチンの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Recombinant Vaccines market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.3% in the forecast period of 2020 to 2025 and will expected to reach USD 935.1 million by 2025, from USD 822.7 million in 2019. The Recombinant Vacci…
- 細菌ワクチンの世界市場 2020年：企業別、地域別、種類・用途別 Market Overview The global Bacterial Vaccines market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Bacterial Vaccines market …